Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

With Hong Kong's IPO market showing a good recovery in 2024 and more stimulus measures launched by China since September 2024 ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

CHINESE soda maker Dayao is gearing up for a Hong Kong initial public offering (IPO) as early as the second half of 2025, ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

Seven IPOs and one SPAC priced this past week, as more sizable issuers filed to go public in the US. Read more here.

EcoCeres Inc., a producer of sustainable fuel backed by Bain Capital, is exploring an initial public offering that could ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

The Inner Mongolia-based maker of carbonated beverages, juices and protein drinks is working with advisers on the size and ...